Investors turn to basic research as they face uncertainties in China

25 September 2023
china_flag_big

By Wang Fangqing

China’s tension between the US-led West, its down-sliding economy and the increasingly wayward policy making all added to the factors that made investors seek different ways to grow their businesses in the country, said speakers at ChinaBio partnering forum held on September 20 in Shanghai.

“Investors are getting extra conservative these days because of the fear of unpredictability. We had always had predictability until two years ago,” said Fay Xing, partner at Panacea Venture, a US dollar denominated fund with offices in the USA and China.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology